ArticleScientific reports2026
Interplay between autophagy and p38 MAPK during salinomycin-induced cell death in cisplatin-resistant melanoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma, a highly aggressive skin cancer, often develops resistance to chemotherapies like Cisplatin (CDDP), leading to treatment failure. This study investigates the potential of Salinomycin, an antibiotic known for targeting cancer stem cells and modulating autophagy, in overcoming CDDP resistance. Notably, there is a lack of consensus on the role of Salinomycin-induced autophagy in cell survival or death. In our study, we used several pharmacological inhibitors to extend our understanding of Salinomycin-induced autophagy and its interactions with regulatory proteins, including the anticancer mechanism in cisplatin-resistant melanoma. Our findings reveal that Salinomycin increases expression of autophagy proteins through ER stress-mediated calcium release and p38 MAPK activation; however, inhibiting autophagy using chloroquine or 3-methyladenine increased Salinomycin’s cytotoxic effects. Further analysis showed that, at later stages, lysosomal damage compromises autophagy flux, leading to cytoplasmic vacuole formation. The size and quantity of these vacuoles are regulated by the p38 MAPK pathway, and inhibition of p38 or calpain enhances their formation. Our results highlight the complex relationship between autophagy, ER stress, and MAPK signaling in melanoma cells treated with Salinomycin, offering insights into its potential use as an adjuvant therapy for treating both CDDP-sensitive and -resistant melanoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.